ArticleJournal of inflammation research2026
A Prognostic Model Based on Immune-Inflammatory-Nutritional Indicators for 28-Day Mortality in Sepsis Patients with Acute-on-Chronic Liver Failure.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sepsis and acute-on-chronic liver failure (ACLF) constitute a severe clinical interaction, resulting in alarmingly high short-term mortality rates. Current prognostic models, such as the Sequential Organ Failure Assessment (SOFA) score, lack specificity for this distinct patient group. The pathophysiology of both conditions is critically influenced by immune dysfunction, systemic inflammation, and nutritional deficits. This study sought to develop and validate a novel prognostic model that integrates immune-inflammatory-nutritional indicators to enhance the prediction of 28-day mortality in sepsis patients with ACLF. Methods: A retrospective cohort study was conducted involving 246 sepsis patients with ACLF admitted to Shaanxi Provincial People's Hospital. Participants were randomly divided into a training cohort (n=185) and a validation cohort (n=61). Least absolute shrinkage and selection operator (LASSO) regression and multivariate logistic regression analyses were utilized to identify independent predictors and construct a prognostic nomogram. The model's efficacy was thoroughly evaluated based on its discriminative capacity (area under the receiver operating characteristic curve, AUC), calibration (calibration curves), and clinical utility (decision curve analysis, DCA). Results: The 28-day mortality rate was observed to be 37.0%. Six independent predictors were identified and integrated into the nomogram: hepatic encephalopathy, D-dimer levels, platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), ALBI grade, and the systemic inflammation response index (SIRI). The nomogram exhibited exceptional discriminative ability, with AUC values of 0.907 and 0.862 in the training and validation cohorts, respectively, significantly surpassing the performance of the SOFA score (AUCs: 0.651 and 0.624). Calibration curves indicated excellent concordance between predicted and observed outcomes, while DCA confirmed a substantial clinical net benefit across a broad range of threshold probabilities. Conclusion: We have successfully developed and validated a robust nomogram that utilizes routinely available immune-inflammatory-nutritional indicators to provide individualized risk estimation of 28-day mortality in sepsis patients with ACLF. This model represents an advanced prognostic instrument when compared to traditional scoring systems, with the potential to enable early detection of high-risk patients and inform individualized therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.